% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Kasakovski:168669,
      author       = {D. Kasakovski$^*$ and M. Skrygan and T. Gambichler and L.
                      Susok},
      title        = {{A}dvances in {T}argeting {C}utaneous {M}elanoma.},
      journal      = {Cancers},
      volume       = {13},
      number       = {9},
      issn         = {2072-6694},
      address      = {Basel},
      publisher    = {MDPI},
      reportid     = {DKFZ-2021-00977},
      pages        = {2090},
      year         = {2021},
      note         = {#EA:A190#DKFZ-ZMBH Alliance},
      abstract     = {To date, the skin remains the most common cancer site among
                      Caucasians in the western world. The complex, layered
                      structure of human skin harbors a heterogenous population of
                      specialized cells. Each cell type residing in the skin
                      potentially gives rise to a variety of cancers, including
                      non-melanoma skin cancer, sarcoma, and cutaneous melanoma.
                      Cutaneous melanoma is known to exacerbate and metastasize if
                      not detected at an early stage, with mutant melanomas
                      tending to acquire treatment resistance over time. The
                      intricacy of melanoma thus necessitates diverse and
                      patient-centered targeted treatment options. In addition to
                      classical treatment through surgical intervention and radio-
                      or chemotherapy, several systemic and intratumoral
                      immunomodulators, pharmacological agents (e.g., targeted
                      therapies), and oncolytic viruses are trialed or have been
                      recently approved. Moreover, utilizing combinations of
                      immune checkpoint blockade with targeted, oncolytic, or
                      anti-angiogenic approaches for patients with advanced
                      disease progression are promising approaches currently under
                      pre-clinical and clinical investigation. In this review, we
                      summarize the current 'state-of-the-art' as well as discuss
                      emerging agents and regimens in cutaneous melanoma
                      treatment.},
      subtyp        = {Review Article},
      keywords     = {cancer therapy (Other) / combination therapy (Other) /
                      immunotherapy (Other) / intratumoral therapy (Other) /
                      melanoma (Other) / skin cancer (Other) / targeted therapy
                      (Other)},
      cin          = {A190},
      ddc          = {610},
      cid          = {I:(DE-He78)A190-20160331},
      pnm          = {311 - Zellbiologie und Tumorbiologie (POF4-311)},
      pid          = {G:(DE-HGF)POF4-311},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:33925915},
      doi          = {10.3390/cancers13092090},
      url          = {https://inrepo02.dkfz.de/record/168669},
}